Flumazenil has a short elimination half-time, which may lead to what phenomenon?

Flumazenil has a short elimination half-time, which may lead to what phenomenon?

• A. Prolonged reversal
• B. Re-sedation after initial recovery
• C. No risk of re-sedation
• D. Prolonged analgesia

Answer: (B)

Flumazenil acts quickly but is short-acting, so its ability to block benzodiazepine effects fades before all of the benzodiazepine has cleared from the body. When that happens, the remaining benzodiazepine can rebind receptors and re-establish sedation, leading to re-sedation after an initial recovery. This risk is higher with long-acting benzodiazepines or when a large or sustained dose was used, so patients may require repeated doses or a short infusion of flumazenil and careful monitoring after reversal. The other options don’t fit because the issue isn’t a longer-than-expected reversal, a guaranteed absence of re-sedation, or an analgesic effect—flumazenil doesn’t address analgesia and its brief action can permit sedation to return once it wears off.

Flumazenil acts quickly but is short-acting, so its ability to block benzodiazepine effects fades before all of the benzodiazepine has cleared from the body. When that happens, the remaining benzodiazepine can rebind receptors and re-establish sedation, leading to re-sedation after an initial recovery. This risk is higher with long-acting benzodiazepines or when a large or sustained dose was used, so patients may require repeated doses or a short infusion of flumazenil and careful monitoring after reversal. The other options don’t fit because the issue isn’t a longer-than-expected reversal, a guaranteed absence of re-sedation, or an analgesic effect—flumazenil doesn’t address analgesia and its brief action can permit sedation to return once it wears off.